149 related articles for article (PubMed ID: 11019861)
21. Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains.
Klimtchuk ES; Peterle D; Bullitt E; Connors LH; Engen JR; Gursky O
Amyloid; 2023 Dec; 30(4):364-378. PubMed ID: 37216473
[TBL] [Abstract][Full Text] [Related]
22. Effect of O-glycosylation on amyloid fibril formation of the variable domain in the Vλ6 light chain mutant Wil.
Abe Y; Shibata H; Oyama K; Ueda T
Int J Biol Macromol; 2021 Jan; 166():342-351. PubMed ID: 33127550
[TBL] [Abstract][Full Text] [Related]
23. Structural relationship of kappa-type light chains with AL amyloidosis: multiple deletions found in a VkappaIV protein.
Alim MA; Yamaki S; Hossain MS; Takeda K; Kozima M; Izumi T; Takashi I; Shinoda T
Clin Exp Immunol; 1999 Dec; 118(3):344-8. PubMed ID: 10594550
[TBL] [Abstract][Full Text] [Related]
24. Shoulder-pad sign of amyloidosis: structure of an Ig kappa III protein.
Liepnieks JJ; Burt C; Benson MD
Scand J Immunol; 2001 Oct; 54(4):404-8. PubMed ID: 11555407
[TBL] [Abstract][Full Text] [Related]
25. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
26. Effects of oxidative post-translational modifications on structural stability and self-assembly of λ6 immunoglobulin light chain.
Zottig X; Laporte Wolwertz M; Golizeh M; Ohlund L; Sleno L; Bourgault S
Biophys Chem; 2016 Dec; 219():59-68. PubMed ID: 27744229
[TBL] [Abstract][Full Text] [Related]
27. Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy.
Gu M; Wilton R; Stevens FJ
Contrib Nephrol; 2007; 153():156-81. PubMed ID: 17075229
[TBL] [Abstract][Full Text] [Related]
28. The amino acid sequence of a glycosylated AL-chain from a patient with primary amyloidosis.
Myran T; Husby G; Kyle RA; Sletten K
Amyloid; 2004 Jun; 11(2):109-12. PubMed ID: 15478466
[TBL] [Abstract][Full Text] [Related]
29. Amino-terminal identity of co-existent amyloid and non-amyloid immunoglobulin kappa light chain deposits. A human disease to study alterations of protein conformation.
Kaplan B; Vidal R; Kumar A; Ghiso J; Frangione B; Gallo G
Clin Exp Immunol; 1997 Dec; 110(3):472-8. PubMed ID: 9409653
[TBL] [Abstract][Full Text] [Related]
30. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain.
Wally J; Kica G; Zhang Y; Ericsson T; Connors LH; Benson MD; Liepnieks JJ; Murray J; Skinner M; Comenzo RL
Biochim Biophys Acta; 1999 May; 1454(1):49-56. PubMed ID: 10354514
[TBL] [Abstract][Full Text] [Related]
32. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins.
Stevens PW; Raffen R; Hanson DK; Deng YL; Berrios-Hammond M; Westholm FA; Murphy C; Eulitz M; Wetzel R; Solomon A
Protein Sci; 1995 Mar; 4(3):421-32. PubMed ID: 7795526
[TBL] [Abstract][Full Text] [Related]
33. The V kappa III subgroup light chain proteins in AL amyloidosis & autoimmune diseases.
Alim MA; Hara Y; Kaji H; Shinoda T
Indian J Med Res; 2001 Jul; 114():30-5. PubMed ID: 11762204
[TBL] [Abstract][Full Text] [Related]
34. A role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle MR; Helms LR; Li L; Chan W; Wetzel R
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5446-50. PubMed ID: 8202506
[TBL] [Abstract][Full Text] [Related]
35. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
36. Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis.
Vora M; Kevil CG; Herrera GA
Ultrastruct Pathol; 2017; 41(5):358-368. PubMed ID: 28796568
[TBL] [Abstract][Full Text] [Related]
37. Constant region of a kappa III immunoglobulin light chain as a major AL-amyloid protein.
Engvig JP; Olsen KE; Gislefoss RE; Sletten K; Wahlström O; Westermark P
Scand J Immunol; 1998 Jul; 48(1):92-8. PubMed ID: 9714416
[TBL] [Abstract][Full Text] [Related]
38. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
39. The pathogenesis and biochemistry of amyloidosis.
Cohen AS; Connors LH
J Pathol; 1987 Jan; 151(1):1-10. PubMed ID: 3550020
[TBL] [Abstract][Full Text] [Related]
40. Isolation and characterization of a kappa amyloid fibril protein.
Gertz MA; Skinner M; Cohen AS; Connors LH; Kyle RA
Scand J Immunol; 1985 Sep; 22(3):245-50. PubMed ID: 2864740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
